ClearPoint Neuro to Present at the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference

Rhea-AI Summary

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced its participation in the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference on April 7, 2022, at 2:30 p.m. Eastern Time. The company specializes in navigating and delivering therapies to treat complex neurological disorders with precision. Its FDA-cleared ClearPoint® Neuro Navigation System is in around 60 active sites across North America and Europe. Currently, ClearPoint is collaborating with approximately 40 pharmaceutical firms and has supported over 5,000 clinical cases globally.

SOLANA BEACH, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference on Thursday, April 7, 2022 at 2:30 p.m. Eastern Time.

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint^® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in approximately 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with approximately 40 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 5,000 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

ClearPoint Neuro Contact:

Danilo D’Alessandro, Chief Financial Officer
1-888-287-9109
info@clearpointneuro.com

Caroline Corner, Investor Relations
ir@clearpointneuro.com

FAQ

When will ClearPoint Neuro present at the B. Riley Securities Mini Conference?

ClearPoint Neuro will present on April 7, 2022, at 2:30 p.m. Eastern Time.

What is ClearPoint Neuro's main focus?

ClearPoint Neuro focuses on enabling therapies for complex neurological disorders with precise navigation and delivery.

How many active sites utilize the ClearPoint Neuro Navigation System?

The ClearPoint Neuro Navigation System is installed in approximately 60 active sites across the U.S., Canada, and Europe.

How many cases has ClearPoint Neuro supported?

ClearPoint Neuro has supported over 5,000 clinical cases to date.

What partnerships does ClearPoint Neuro have?

ClearPoint Neuro is partnered with around 40 biologics and pharmaceutical companies for CNS therapeutic delivery.